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Abstract 22 
Aims  Predicting likely durability of glucose-lowering therapies for people with type 2 23 
diabetes (T2D) could help inform individualised therapeutic choices. 24 
Methods  We used data from UKPDS patients with newly-diagnosed T2D randomised to 25 
first-line glucose-lowering monotherapy with chlorpropamide–glibenclamide–basal insulin or 26 
metformin. In 2,339 participants who achieved one-year HbA1c values <7.5% (<59 27 
mmol/mol)–we assessed relationships between one-year characteristics and time to 28 
monotherapy-failure (HbA1c ≥7.5% or requiring second-line therapy). Model validation was 29 
performed using bootstrap sampling. 30 
Results  Follow-up was median (IQR) 11.0 (8.0–14.0) years. Monotherapy-failure occurred 31 
in 72%–82%–75% and 79% for those randomised to chlorpropamide–glibenclamide–basal 32 
insulin or metformin respectively–after median 4.5 (3.0–6.6)–3.7 (2.6–5.6)–4.2 (2.7–6.5) and 33 
3.8 (2.6– 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA1c and BMI 34 
values–with other risk factors varying by type of monotherapy–with predictions to within ±2.5 35 
years for 55%–60%–56% and 57% of the chlorpropamide–glibenclamide–basal insulin and 36 
metformin monotherapy cohorts respectively. 37 
Conclusions  Post one-year glycaemic durability can be predicted robustly in individuals 38 
with newly-diagnosed T2D who achieve HbA1c values <7.5% one year after commencing 39 
traditional monotherapies. Such information could be used to help guide glycaemic 40 
management for individual patients. 41 
42 
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Introduction 61 
The ADA/EASD Position Statement for the management of hyperglycaemia in type 2 62 
diabetes (T2D) recommends a patient-centred approach to identifying the most appropriate 63 
glucose-lowering therapy for a given individual.[1] However–no specific guidance is provided 64 
as to how best to select the most durable glycaemic agent for any one individual. One 65 
strategy which could help make the most effective use of available glucose-lowering 66 
therapies is to target treatment to those who are most likely to respond to therapy–an 67 
approach known as stratified–or precision medicine.[2] 68 
At a population level–mean HbA1c levels in people with newly-diagnosed T2D 69 
decrease initially with therapy and then rise over time–necessitating multiple glucose-70 
lowering therapies.[3] This biphasic pattern is sometimes referred to as the “Nike Curve” as 71 
it resembles the Nike "swoosh" trademark. While substantial research has been published 72 
investigating potential predictors of initial response to glucose lowering therapy–whether 73 
durability of individual therapies varies by participant characteristics and can be predicted 74 
has not been previously investigated. The MRC/APBI funded STratification and Extreme 75 
Response Mechanism IN Diabetes (MASTERMIND) consortium felt that the biphasic 76 
glucose curve in T2D would best be modelled by addressing the initial glycaemic drop with 77 
therapy and then–separately–its subsequent rise. This paper examines the development of 78 
models that predict the rise in glucose values during the second upward phase–taking into 79 
account the first-year response. Individual patient upward HbA1c trajectories  are difficult to 80 
predict given their often apparently random variation–although a DIRECT study of the 81 
clinical and genetic determinants of glycaemic progression in patients with T2D suggested 82 
that increased triglyceride and low HDL-cholesterol levels were independently associated 83 
with an increased rate of progression of diabetes.[4] In clinical practice, however, it remains 84 
unclear at an individual patient level which factors most affect durability of glycaemic 85 
response to glucose-lowering therapies.   86 
Potential predictors were investigated for the post one-year glycaemic durability of 87 
the glucose-lowering monotherapies allocated at random as first-line therapy to patients with 88 
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newly-diagnosed T2D enrolled into the UK Prospective Diabetes Study (UKPDS).[5] UKPDS 89 
participants were assigned at random to monotherapy with chlorpropamide, glibenclamide, 90 
basal insulin or metformin (only if >120% ideal body weight). In those who achieved 91 
acceptable HbA1c values at one year, we sought to predict the time at which their glycaemic 92 
control would worsen to the point when the addition of second-line glucose-lowering therapy 93 
would likely be indicated by many guidelines.  94 
 95 
Subjects 96 
We used data from UKPDS patients. Details of UKPDS recruitment, inclusion and exclusion 97 
criteria, protocol and trial results have been published.[5-7] Briefly, patients with newly-98 
diagnosed T2D who were allocated to the UKPDS intensive glucose control arm were 99 
randomised to first-line glucose-lowering monotherapy with chlorpropamide (a first-100 
generation sulfonylurea), glibenclamide (a second generation sulfonylurea), basal insulin or 101 
metformin (only if >120% ideal body weight). The aim of the intensive glucose control arm 102 
was to achieve and maintain fasting plasma glucose (FPG) levels <6.0 mmol/l by increasing 103 
monotherapy doses as necessary to the maximum permitted or tolerated, based on 3-104 
monthly FPG measurements. Glycaemic rescue, with the addition of a second protocol-105 
specified glucose-lowering agent, was only permitted if repeated FPG values were >15.0 106 
mmol/l or if hyperglycaemic symptoms had become unacceptable. The participants selected 107 
for this study were those at one-year who remained on their allocated monotherapy, had an 108 
HbA1c <7.5% (<59 mmol/mol) at 1 year, and who had the requisite analytic data available. 109 
 110 
Materials and Methods  111 
For the purposes of this analysis monotherapy failure, i.e. the need for a second line 112 
glucose-lowering therapy, was defined as an HbA1c ≥7.5% (≥59 mmol/mol) or the UKPDS 113 
protocol-driven requirement for glycaemic rescue. Post one-year time-to-monotherapy-114 
failure times were calculated as the interval between the one-year visit and the time when 115 
either of the indications for monotherapy failure were met. As HbA1c values were only 116 
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measured annually,[5] we used linear interpolation to estimate time points between visits 117 
when values likely became ≥7.5% (≥59 mmol/mol). 118 
The two outcomes of interest for each monotherapy were: 1) The median post one-119 
year time-to-monotherapy-failure; 2) The degree to which this time point could be predicted 120 
from the one-year demographic, phenotypic and laboratory data available. We developed a 121 
BASIC model using only those variables likely to be available in routine clinical practice, i.e. 122 
HbA1c, age, sex, ethnicity, smoking, body mass index (BMI), plasma creatinine, total 123 
cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), plasma triglycerides and 124 
estimated glomerular filtration rate (eGFR), and an EXTENDED model that included 125 
additional variables collected as part of the UKPDS protocol, i.e. fasting plasma glucose 126 
(FPG), fasting plasma insulin (FPI), HOMA2_%B, HOMA2_%S and urinary creatinine. 127 
 128 
Statistical Analysis 129 
Complete case (CC) and multiple-imputed complete data (MICD) datasets were used to 130 
construct the BASIC and the EXTENDED models, with missing data imputed by multiple 131 
imputation function in R (aregImpute). The mechanisms and patterns of missing data were 132 
investigated by employing further R functions (naclus and naplot) for a cluster analysis 133 
investigating missing values status and graphical representation of missing patterns. CC and 134 
MICD datasets from each monotherapy cohort were used to develop models and validated 135 
using a bootstrapping procedure. MICD sensitivity analyses were used to check that any 136 
missing data did not bias complete case model estimates. HOMA2_%B and HOMA2_%S 137 
values were derived from FPG and FPI levels using the HOMA2 Calculator,[8] and eGFR 138 
values were calculated using the Modification of Diet in Renal Disease (MDRD) formula.[9]  139 
Univariate accelerated failure time (AFT) regression modelling was used to 140 
investigate the relationship between variables measured at one year and the subsequent 141 
time-to-monotherapy-failure, based on a log-logistic three-parameter distribution.  We 142 
optimised potential associations by examining alternative distributions, e.g. log, square, 143 
square root, etc., and the best fit with the simplest form for clinical interpretation chosen. A 144 
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statistical significance level of p≤0.1 was used in univariate AFT regression analyses to 145 
select which variables would be included in multivariate AFT regression analyses.  146 
A multivariable AFT regression was performed in separate prognostic models for 147 
each monotherapy cohort to assess independent associations between one-year covariates 148 
and subsequent time-to-monotherapy-failure. The final model variables were decided by 149 
backward selection procedures during which individual model outputs (regression 150 
coefficients, p-values, Akaike information criterion (AIC), Bayesian information criterion 151 
(BIC), and log likelihood value were monitored. All models were validated internally for their 152 
discrimination and predictive abilities using bootstrap sampling. In addition, the relative 153 
performance of the basic and extended models was evaluated by comparing their estimated 154 
information criteria (AIC and BIC). 155 
All statistical analyses were performed with Regression Modelling Strategies (RMS) 156 
Package (Version 5.0-0, 2016-10-31), R-3.4.3 for Windows (Copyright© 2015, The R 157 
Foundation for Statistical Computing) and STATA version 15.0 (StataCorp LP 4905 Lakeway 158 
Drive College Station, Texas 77845-4512 USA). 159 
 160 
Results 161 
Of the 5102 patients enrolled into the UKPDS, 2110 (41%) were included in the MICD 162 
dataset who fulfilled our criteria for this analysis and who had achieved an HbA1c <7.5% 163 
(<59 mmol/mol) at one year. They had been assigned at random to chlorpropamide (N=573, 164 
27%), glibenclamide (N=462, 22%), basal insulin (N=828, 39%) or metformin (N=247, 18%) 165 
with a median (IQR) post one-year follow-up of 11.0 (8.0, 14.0) years (Supplementary 166 
Appendix Fig. S1) . There were too few patients allocated to glipizide (N=170) in UKPDS 167 
Glucose Study II[5] to be included in this analysis. Table 1  lists the one-year variables 168 
utilised, their summary statistics, the proportions of missing data and the modelling 169 
approaches used. There were no missing values for age, sex, race or smoking, whilst the 170 
proportions of missing data for total cholesterol, LDL-C, HDL-C, triglycerides, creatinine, 171 
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fasting plasma glucose, insulin, eGFR, HOMA2_%B and HOMA2_%S ranged from 9% to 172 
27%.  173 
In the MICD data set, post one-year monotherapy-failure occurred in 76% (1607/2110) 174 
participants, comprising 72% (415/573) for chlorpropamide, 82% (378/462) for 175 
glibenclamide, 75% (620/828) for basal insulin, and 79% (194/247) for metformin. The 176 
overall proportion of these participants requiring glycaemic rescue per protocol was 4.7% 177 
(99/2110), being 7.7% (44/573) for chlorpropamide, 9.7% (45/462) for glibenclamide, 0.2% 178 
(2/828) for basal insulin and 3.2% (8/247) for metformin. 179 
The number of patients in the complete case data set was 1438 (82% of the MICD dataset) 180 
with the proportions randomised to each glucose-lowering monotherapy being 70% 181 
(399/573) for chlorpropamide, 67% (318/462) for glibenclamide, 67% (557/828) for basal 182 
insulin and 66% (164/247) for metformin. 183 
 184 
BASIC model predictors of time-to-monotherapy-failure using routinely available data 185 
Overall, the median (IQR) time-to-monotherapy-failure was 4.0 (2.0, 8.0) years. This time 186 
differed by monotherapy being 4.5 (3.0, 6.6) years for chlorpropamide, 3.7 (2.6, 5.6) years 187 
for glibenclamide, 4.2 (2.7, 6.) years for basal insulin and 3.8 (2.6, 5.2) years for metformin. 188 
In univariate analyses, time-to-monotherapy-failure increased with higher age, lower BMI, 189 
male sex and being White Caucasian. (Supplementary Appendix Table S1 ).  190 
In the CC multivariate BASIC model, one-year HbA1c and BMI were predictive factors 191 
for all monotherapies, with higher values associated with a shorter time-to-monotherapy-192 
failure (Table 2 ). Additional factors by monotherapy cohort were: chlorpropamide (age, sex, 193 
ethnicity, smoking, LDL-C and triglycerides; glibenclamide (age and triglycerides); basal 194 
insulin (age, total cholesterol and HDL-C); metformin (none). The magnitude and direction of 195 
the different effect sizes are listed in Table 2  as failure time ratios with 95% confidence 196 
limits. The findings for the equivalent BASIC MICD multivariate model analyses were all 197 
similar (Supplementary Appendix Table S2 ). 198 
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 199 
EXTENDED model predictors of time-to-monotherapy-failure 200 
The median time-to-monotherapy-failure predicted by the extended model with additional 201 
variables for each monotherapy cohort was 4.7 (3.0, 6.9) years for chlorpropamide, 4.0 (2.6, 202 
6.0) years for glibenclamide, 3.9 (2.6, 6.1) years for insulin, and 3.8 (2.6, 5.2) years for 203 
metformin. (Table 2).  204 
In the CC multivariate EXTENDED model, one-year HbA1c and BMI were predictive factors 205 
for all monotherapies, with higher values of both associated with a shorter time-to-206 
monotherapy-failure. Additional factors by monotherapy cohort were: chlorpropamide (age, 207 
ethnicity, smoking, LDL-C, FPG and HOMA2_%B); glibenclamide (age, ethnicity and FPG); 208 
basal insulin (age, smoking, FPI, HOMA2_%B and HOMA2_%S); metformin (none).  The 209 
magnitude and direction of the different effect sizes are listed in Table 2 . The findings for the 210 
equivalent EXTENDED model MICD analyses were all similar (Supplementary Appendix 211 
Table S2 ). 212 
The results of the internal validation, the discrimination and calibration bootstrap 213 
corrected indices (Nagelkerke R2, Somers’ D[Dxy], and shrinkage factor [Slope]) are shown 214 
in Table 2 . The discrimination indices, R2 and Dxy, range from 15.0%–29.3% and 0.3058-215 
0.4062 across cohorts and models, respectively. The bootstrap corrected slopes were 216 
greater than 90% across cohorts and models. Similar results were obtained for the MICD 217 
models (Supplementary Appendix Table S2 ). 218 
The smaller AIC and BIC values for the extended models show that they fit the data better 219 
for all the monotherapies than the basic models, except for metformin.  220 
     221 
Predictive equations 222 
The predictive equations for individual patient time-to-monotherapy-failure derived from the 223 
BASIC and EXTENDED models are shown in Supplementary Appendix Figures S2 and 224 
S3 respectively. The performance of these equations for the BASIC and EXTENDED models 225 
are depicted in Fig. 1 and Supplementary Appendix Fig. S4 , comparing the differences 226 
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between predicted and observed time-to-monotherapy-failure with the observed time-to-227 
monotherapy-failure for each monotherapy cohort. For the BASIC model, the post one-year 228 
time-to-monotherapy-failure was predictable to within ±2.5 years for 55%, 60%, 56% and 229 
57% of individuals allocated to chlorpropamide, glibenclamide, basal insulin and metformin 230 
monotherapy respectively. The corresponding proportions for the EXTENDED model were 231 
56%, 61%, 59% and 57% respectively. 232 
Median time-to-monotherapy-failure predictions, calculated for each monotherapy for 233 
five example patients using the BASIC model, are illustrated in Table 3 , showing a different 234 
rank order for monotherapy durability depending on patient’s one-year characteristics. The 235 
equivalent predictions for the EXTENDED models are shown in Supplementary Appendix 236 
Fig. S5 . 237 
 238 
Discussion 239 
These analyses show that the post one-year durability of glycaemic control for the majority 240 
of individuals with newly-diagnosed T2D who have an HbA1c <7.5% one year after 241 
commencing treatment with chlorpropamide, glibenclamide, basal insulin or metformin 242 
monotherapies, can be estimated to within ±2.5 years for around half of the patients in each 243 
monotherapy cohort. Application of the predictive equations showed that a hierarchy of 244 
glycaemic durability can be derived using routinely available clinical information. Such 245 
information could be used in the management of tyT2D to help guide therapeutic choices for 246 
individual patients. 247 
It is of interest that for most of the monotherapies studied it is largely the same 248 
factors that predict glycaemic durability, with a lower one-year HbA1c, lower one-year BMI 249 
and higher age of diabetes diagnosis onset favouring greater durability.  This fits with the 250 
previous paper by Zhou et al [4] that showed higher BMI, HbA1c and a younger age of 251 
diagnosis were associated with more rapid progression to insulin.  A key finding of our study 252 
is that these factors have a different quantitative impact on different therapies explaining why 253 
there is overall a difference in durability between therapies.  Previous studies have 254 
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compared glycaemic durability with different agents [11] but have not examined the factors 255 
which are predictive for individuals.   256 
The strengths of these analyses include the randomised allocation of therapies from 257 
diagnosis of T2D and the unusually long follow-up period as a consequence of the UKPDS 258 
protocol requirement for glycaemic rescue only when FPG values became >15.0 mmol/l or 259 
hyperglycaemic symptoms became unacceptable. Limitations include the lack of data for 260 
other indicators possibly related to the modes of action of the therapies examined, e.g. 261 
fasting and postprandial C-peptide levels which were not collected in the UKPDS, as well as 262 
the relatively small sample sizes. The proportions of missing data could also be a concern 263 
but these were either missing completely at random, or missing at random, with the MICD 264 
sensitivity analyses showing no evidence of missing data biasing the results. The two 265 
sulfonylureas (chlorpropamide and glibenclamide) analysed here are no longer 266 
recommended in routine clinical practice but the methodology we have used could be 267 
applied to more contemporaneous datasets to estimate the likely durability of newer 268 
glucose-lowering agents. 269 
Routinely available phenotypic and laboratory data in people with newly-diagnosed T2D, 270 
who have achieved an HbA1c <7.5% (<59 mmol/mol) on monotherapy with chlorpropamide, 271 
glibenclamide, basal insulin or metformin at one year after diagnosis, can be used to 272 
estimate the likely glycaemic durability of continued monotherapy. Such information could be 273 
used to help guide individualised patient management.  274 
275 
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Figure Legend 342 
Fig. 1. Comparison of the differences between the complete case basic model predicted and 343 
the observed time-to-monotherapy-failure (observed minus predicted), with the observed 344 
time-to-monotherapy-failure. Panel A: Chlorpropamide, Panel B: Glibenclamide, Panel C: 345 
Basal insulin, Panel D: Metformin. The dotted horizontal lines depict ±2.5 years. 346 
 347 
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Table 1. Variables included in the basic and extended models.     
    
  Number with missing data n (%)  
 Summary Chlorpropamide Glibenclamide Insulin Metformin Modelling 
 Variable statistics* [573] [462] [828] [247] methodology 
HbA1c (%) 5.9 (0.8) 573 (0%) 462 (0%) 828 (0%) 247 (0%) Linear 
Age (years) 54 (47.859.7) 573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical 
Sex  573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical 
Male 1128 (61.3%)     
 
Female 712 (38.7%)     
 
Ethnicity  573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical 
 Caucasian 1554 (84.5%)     
 
Non-Caucasian 286 (15.5%)     
 
Smoking  573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical 
Non-Smoker 640 (34.8%)     
 
Ex-Smoker 647 (35.2%)     
 
Smoker 553 (30.0%)     
 
BMI (kg/m2) 27.3 (24.7–30.8) 521 (9%) 409 (11%) 751 (9%) 214 (13%) Logarithm 
Plasma creatinine (μmol/L) 83.8 (17.2) 444 (23%) 370 (20%) 645 (22%) 189 (23%) Linear 
Total cholesterol (mmol/L) 5.4 (1.1) 439 (23%) 353 (24%) 632 (24%) 179 (28%) Linear 
LDL-cholesterol (mmol/L) 3.5 (1) 433 (24%) 347 (25%) 616 (26%) 175 (29%) Linear 
HDL-cholesterol (mmol/L) 1.1 (0.3) 434 (24%) 350 (24%) 623 (25%) 176 (29%) Linear 
Plasma triglycerides (mmol/L) 1.5 (1.1–2.1) 436 (24%) 345 (25%) 624 (25%) 181 (27%) Logarithm 
eGFR (ml/min/1.73m2) 79.5 (18.1) 444 (23%) 370 (20%) 645 (22%) 189 (23%) Linear 
Extended Model      
 
(additional variables) 
Fasting plasma glucose (mmol/l) 6.8 (1.5) 516 (10%) 407 (12%) 747 (10%) 212 (14%) Linear 
Fasting plasma insulin (mu/l) 13.9 (9.6–19.6) 440 (23%) 355 (23%) 618 (25%) 183 (26%) Logarithm 
HOMA2_%B 80.9 (57.8–112.3) 430 (25%) 349 (24%) 601 (27%) 180 (27%) Logarithm 
HOMA2_%S 53.5 (37.8–76.2) 430 (25%) 349 (24%) 601 (27%) 180 (27%) Logarithm 
Urinary creatinine (µmol/l) 10.3 (5.9) 447 (22%) 365 (21%) 640 (23%) 189 (23%) Linear 
*Summary statistics are mean (SD) or median (IQR) for continuous variables, and number (%) for categorical variables 
348 
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 349 
Table 2. Complete case (CC) multivariate analyses showing monotherapy failure time ratios and 95% confidence intervals. 
 Chlorpropamide Glibenclamide Insulin Metformin 
Basic Model Variables TR [95% CI] P-Value TR [95% CI] P-Value TR [95% CI] 
P-
Value TR [95% CI] 
P-
Value 
HbA1c (%) 0.65 [0.57–0.74] 0.000 0.56 [0.49–0.65] 0.000 0.54 [0.48–0.61] 0.000 0.56 [0.46–0.69] 0.000 
Age (years)         
<40   1  1  1  1  
40-44   1.32 [0.82–2.14] 0.256 1.45 [0.76–2.77] 0.254 1.17 [0.71–1.93] 0.536 - - 
45-49   1.39 [0.88–2.20] 0.160 1.58 [0.86–2.88] 0.139 1.10 [0.70–1.72] 0.694 - - 
50-54   1.68 [1.12–2.52] 0.012 1.89 [1.05–3.40] 0.035 1.56 [1.00–2.42] 0.049 - - 
55-59   1.60 [1.07–2.40] 0.023 2.06 [1.15–3.69] 0.015 1.81 [1.16–2.82] 0.009 - - 
60-64   1.95 [1.30–2.91] 0.001 2.14 [1.21–3.80] 0.009 1.99 [1.27–3.11] 0.003 - - 
>64   2.02 [1.15–3.53] 0.014 2.31 [1.15–4.66] 0.019 1.82 [1.09–3.05] 0.022 - - 
Sex          
Male   1  1  1  1  
Female   1.18 [0.95–1.48] 0.136 - - - - - - 
Race          
Caucasian   1  1  1  1  
Non-Caucasian   0.71 [0.53–0.94] 0.016 - - - - - - 
Smoking          
Non-Smoker   1  1  1  1  
Ex-Smoker   1.36 [1.04–1.79] 0.027 - - - - - - 
Smoker   0.97 [0.75–1.26] 0.838 - - - - - -          
Log BMI (kg/m2) 0.27 [0.15–0.49] 0.000 0.24 [0.12–0.46] 0.000 0.37 [0.22–0.62] 0.000 0.31 [0.11–0.93] 0.037 
Plasma creatinine (μmol/L) - - - - - - - - 
Total cholesterol (mmol/L) - - - - 0.93 [0.86–1.02] 0.112 - - 
LDL-C (mmol/L) 0.90 [0.81–1.01] 0.067 - - - - - - 
HDL-C (mmol/L) - - - - 1.36 [0.96–1.92] 0.085 - - 
Log Triglycerides (mmol/L) 0.80 [0.65–1.00] 0.047 0.86 [0.70–1.06] 0.169 - - - - 
eGFR (ml/min/1.73m2) - - - - - - - - 
Information criteria 
          AIC 1068.193  894.8231  1564.809  573.8394  
          BIC 1013.907  1022.962  1512.145  573.8394  
Bootstrap internal validation corrected-
index         
          R2 0.1983  0.2359  0.2019  0.1503  
          Somers’ Dxy 0.3420  0.3655  0.3518  0.3058  
          Calibration slope 0.9074  0.9377  0.9427  0.9948  
Model estimated failure time 
Median[IQR] 4.5 [3.0–6.6]  3.7 [2.6–5.6]  4.2 [2.7–6.5]  3.8 [2.6–5.2]  
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Extended Model Variables - - - - - - - - 
HbA1c (%) 0.71 [0.62–0.81] 0.000 0.65 [0.58–0.74] 0.000 0.56 [0.50–0.63] 0.000 0.56 [0.46–0.69] 0.000 
Age (years)         
<40   1  1  1  1  
40-44   1.21 [0.76–1.91] 0.422 1.39 [0.80–2.42] 0.240 1.21 [0.75–1.95] 0.461 - - 
45-49   1.31 [0.85–2.03] 0.218 1.62 [0.97–2.70] 0.063 1.18 [0.77–1.82] 0.533 - - 
50-54   1.54 [1.04–2.26] 0.029 1.55 [0.94–2.55] 0.084 1.64 [1.08–2.51] 0.031 - - 
55-59   1.54 [1.04–2.26] 0.031 1.62 [0.99–2.65] 0.053 1.82 [1.19–2.77] 0.010 - - 
60-64   1.86 [1.26–2.74] 0.002 1.65 [1.02–2.68] 0.043 1.96 [1.28–3.01] 0.004 - - 
>64   1.77 [1.04–3.03] 0.037 1.66 [0.93–2.99] 0.089 1.88 [1.15–3.07] 0.019 - - 
Sex          
Male   1  1  1  1  
Female   - - - - - - - - 
Race          
Caucasian   1  1  1  1  
Non-Caucasian   0.70 [0.54–0.92] 0.010 0.69 [0.53–0.89] 0.005 - - - - 
Smoking          
Non-Smoker   1  1  1  1  
Ex-Smoker   1.15 [0.90–1.47] 0.269 - - 0.91 [0.74–1.12] 0.399 - - 
Smoker   0.84 [0.66–1.07] 0.151 - - 0.77 [0.63–0.95] 0.014 - -          
Log-BMI (kg/m2) 0.26 [0.14–0.47] 0.000 0.26 [0.15–0.46] 0.000 0.41 [0.24–0.70] 0.001 0.31 [0.11–0.93] 0.037 
Plasma creatinine (μmol/L) - - - - - - - - 
Total cholesterol (mmol/L) - - - - - - - - 
LDL-C (mmol/L) 0.92 [0.83–1.01] 0.088 - - - - - - 
HDL-C (mmol/L) - - - - - - - - 
Log Triglycerides (mmol/L) - - - - - - - - 
eGFR (ml/min/1.73m2) - - - - - - - -          
Fasting plasma glucose (mmol/l) 0.81 [0.74–0.88] 0.000 0.80 [0.75–0.86] 0.000     
         
Log HOMA2_%B 0.79 [0.61–1.04] 0.093 - - 1.23 [1.01–1.50] 0.011 - - 
Log HOMA2_%S - - - - 1.44 [1.17–1.77] 0.033 -  
Urinary creatinine (µmol/l) - - - - - - -  
Information criteria         
          AIC 1133.0270  936.9738  1514.873  587.3033  
          BIC 1078.3590  1071.0390  1576.360  587.3033  
Bootstrap internal validation corrected-
index         
          R2 0.2463  0.2931  0.2251  0.1503  
          Somers’ Dxy 0.3640  0.4062  0.3675  0.3058  
          Calibration slope 0.9273  0.9540  0.9434  0.9948  
Model estimated failure time 
Median[IQR] 4.7 [3.0–6.9]  4.0 [2.6–6.0]  3.9 [2.6–6.1]  3.8 [2.6–5.2]  
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Table 3. Median time-to-failure (durability) calculated using the basic model equations and shown in rank order for six examplar cases. 351 
 
Case  1 Case  2 Case  3 Case  4 Case  5 Case 6 
HbA1c (%) 5.0 5.5 6 6.5 7 7.5 
Age (years) 65 60 55 50 45 40 
BMI (kg/m2) 25.0 27.0 29.0 31.0 33.0 35.0 
Sex Male Female Male Female Male Male 
Race Caucasian Non Caucasian Caucasian Non Caucasian Caucasian Non Caucasian 
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Fig. 1 354 
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